Tepilukimig

替匹鲁奇米单抗

Report date: 2026/04/17 20:02:02

Base Information

Drug NameTepilukimig
Drug Alias NameGR2002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsDermatitis, AtopicNasal PolypsAsthma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenrix (Shanghai) Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicNasal PolypsAsthma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A